Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD84-CD3 bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Shanghai Symray Biopharma
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD84-CD3 bispecific antibody is an experimental bispecific T-cell engager (BiTE) developed for the treatment of acute myeloid leukemia (AML). The therapeutic is designed to simultaneously target CD84 (also known as SLAMF5), a signaling lymphocytic activation molecule family member that is highly expressed on AML blasts and leukemia stem cells, and the CD3 subunit of the T-cell receptor complex. By bridging these two targets, the antibody facilitates the formation of an immunological synapse, redirecting T-cell-mediated cytotoxic activity specifically against CD84-positive leukemic cells. Preclinical studies conducted by Shanghai Symray Biopharma have demonstrated that lead candidates, such as #24 and #26, achieve potent anti-leukemic activity and prolonged survival in xenograft and patient-derived models. Notably, CD84 expression is minimal on normal hematopoietic stem cells (HSCs), potentially offering a wider therapeutic window and reduced myelotoxicity compared to agents targeting CD33 or CD123.
- Other names
- CD84-CD3 BiTECD-84-CD3 BiTECD 84-CD3 BiTE
02
Targets
CD3 (T-cell surface glycoprotein CD3)SLAMF5 (Signaling lymphocyte activation molecule family member 5)
Beyond the preview
Go deeper on CD84-CD3 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD84-CD3 bispecific antibody.